Hutchison China Meditech Limited Notification of Dilution of Voting Rights
RNS Number : 4464V
Hutchison China Meditech Limited
14 April 2021
Notification of Dilution of Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April
14, 2021: Hutchison China MediTech Limited ("HUTCHMED")
(Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited
(" CK Hutchison ") shareholding() in HUTCHMED remains unchanged,
at 332,478,770 ordinary shares of par value US$0.10 each in the
capital of HUTCHMED ("Shares").
Each American Depositary Share ("ADS") represents five Shares.
As announced on April 8, 2021, HUTCHMED issued a total of
16,393,445 Shares (equivalent to 3,278,689 ADSs) to funds
affiliated with Baring Private Equity Asia. HUTCHMED was notified
on April 14 , 2021 that this issuance diluted CK Hutchison's
holding() to 44.66 per cent of the total number of voting rights
of HUTCHMED. The date on which the notification threshold was
crossed was April 14 , 2021.
() Held through CK Hutchison's indirect wholly-owned
subsidiary Hutchison Healthcare Holdings Limited.
HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and
global development and commercialization of targeted therapies and
immunotherapies for the treatment of cancer and immunological
diseases. A dedicated organization of over 1,200 personnel has
advanced ten cancer drug candidates from in-house discovery into
clinical studies around the world, with its first two oncology
drugs now approved and launched. For more information, please
visit: www.hutch-med.com or follow us on LinkedIn .
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile) / +852 9783 6894 (Mobile)
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact email@example.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
April 14, 2021 05:30 ET (09:30 GMT)